Search

Displaying results 341 - 350 of 392 in total
  1. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.

  2. Drug

    Galantamine

    go.drugbank.com/drugs/DB00674
    ApprovedInvestigational

    [A203558] Galantamine is marketed under the brand name Razadyne, and is available as oral immediate- and extended-release tablets and solution.[L13571]

  3. Drug

    Octisalate

    go.drugbank.com/drugs/DB11062
    Approved

    Also known as Ethylhexyl Salicylate. Octyl salicylate is an oil soluble chemical sunscreen agent that absorbs UVB radiation. It does not protect against UVA. Octyl salicylate is used to augment the UVB protection in a sunscreen. Salicyla...

    Mixtures: Select Brand Sunscreen, Select Brand Sunscreen
  4. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    It is commonly marketed under the brand name Amaryl as oral tablets and is typically administered once daily.

    Products: GLIMEPIRIDE DOC GENERICI, GLIMEPIRIDE MYLAN GENERICS
  5. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

  6. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists.

  7. Drug

    Diminazene

    go.drugbank.com/drugs/DB03608
    Experimental

    Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. This compound belongs to the phenylhydrazines.

  8. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret.

  9. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion.

  10. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.